Latest Industry Insights

Hans van der Voorn tells us about some of the recent progress in the extracellular vesicle-based diagnostics and therapeutics landscape, particularly the need for industrial-scale EV isolation workflows.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

This article discusses why the proactive detection and monitoring of viral threats through genomics studies is vital in preventing future pandemics and empowering healthcare providers in the face of increasing globalization.

Unlocking more information from our proteome could deepen our understanding of disease, improve detection and influence drug selection. To find out more about single-molecule proteomics, we spoke to Parag Mallick, co-founder of Nautilus Biotech.

To learn more about MIPS and why they are particularly suited for use in in vitro diagnostic assays, we spoke to Dr. Francesco Canfarotta, head of chemistry at MIP Discovery.

The 10-year anniversary of SWATH DIA signifies a period of immense growth that is only expected to continue to evolve, influencing a wide range of fields. This article explores key milestones for SWATH DIA since its development.

Technology Networks spoke with Anjali Pradhan, senior vice president of product management at Mission Bio, to discuss a new application for DNA methylation analysis, and its potential in uncovering new biological insights and biomarkers that may guide the future of cancer research.

To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.

In this opinion piece, Liz Sparrow discusses the real risk of the UK losing its science and technology communities as they face a series of challenges that are threatening their growth.

To learn more about T-cell testing, the types of diseases it can help to diagnose and its value in clinical trials, we spoke to Phill Keefe, chief executive officer of PerkinElmer’s Oxford Immunotec division.